Clinical application of 5-HTa-3R antagonist tropisetron in chemotherapy patients

doi:10.3748/wjg.v1.i1.52

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 1, Issue 1

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3196)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-3) series.

Item

Count

PDF

338

HTML

2392

Tables (1-3)

466

Sum=3196

Oct 1, 1995 (publication date) through Dec 2, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Oct 1, 1995; 1(1): 52-57
Published online Oct 1, 1995. doi: 10.3748/wjg.v1.i1.52

Table 2 Pharmacokinetic parameters of navoban in poor and extensive metabolizers, normalized for a 10 mg dose

Parameter	Extensive metabolisers		Poor metabolisers
Parameter	IV (n = 18)	Oral (n = 43)	IV (n = 36)	Oral (n = 12)
T_max (h)		2		3.6
C_max (μg/L)	84	21.7	82	29.9
AUC (μg/L·h)	239	230	1192	1579
t_1/2β (h)	7.3	8.6	30.3	41.9
V_β (L)	554		463
F (%)	100	60-100^a	100	60-100^a

^a: Dose dependent; T_max: Time to maximum plasma concentration; C_max: Maximum plasma concentration; AUC: Area under plasma concentration-time curve; t_1/2β: Terminal phase elimination half life; V_β: Volume of distribution during termination phase; F: Bioavailability.

Citation: Xu CT, Pan BR. Clinical application of 5-HTa-3R antagonist tropisetron in chemotherapy patients. World J Gastroenterol 1995; 1(1): 52-57
URL: https://www.wjgnet.com/1007-9327/full/v1/i1/52.htm
DOI: https://dx.doi.org/10.3748/wjg.v1.i1.52